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Background: Reduced adiponectin is implicated in the pathogenesis of nonalcoholic fatty liver disease (NAFLD)
and steatohepatitis (NASH), and the I148M Patatin-like phospholipase domain-containing 3 (PNPLA3) polymorphism
predisposes to NAFLD and liver damage progression in NASH and chronic hepatitis C (CHC) by still undefined
mechanisms, possibly involving regulation of adipose tissue function. Aim of this study was to evaluate whether
the I148M PNPLA3 polymorphism influences serum adiponectin in liver diseases and healthy controls.
Methods: To this end, we considered 144 consecutive Italian patients with NAFLD, 261 with CHC, 35 severely
obese subjects, and 257 healthy controls with very low probability of steatosis, all with complete clinical and
genetic characterization, including adiponectin (ADIPOQ) genotype. PNPLA3 rs738409 (I148M) and ADIPOQ
genotypes were evaluated by Taqman assays, serum adiponectin by ELISA. Adiponectin mRNA levels were
evaluated by quantitative real-time PCR in the visceral adipose tissue (VAT) of 35 obese subjects undergoing
bariatric surgery.
Results: Adiponectin levels were independently associated with the risk of NAFLD and with the histological severity
of the disease. Adiponectin levels decreased with the number of 148 M PNPLA3 alleles at risk of NASH both in
patients with NAFLD (p = 0.03), and in healthy subjects (p = 0.04). At multivariate analysis, PNPLA3 148 M alleles were
associated with low adiponectin levels (<6 mg/ml, median value) independently of NAFLD diagnosis, age, gender,
BMI, and ADIPOQ genotype (OR 1.67, 95% c.i. 1.07-2.1 for each 148 M allele). The p.148 M PNPLA3 variant was
associated with decreased adiponectin mRNA levels in the VAT of obese patients (p < 0.05) even in the absence
of NASH. In contrast, in CHC, characterized by adiponectin resistance, low adiponectin was associated with male
gender and steatosis, but not with PNPLA3 and ADIPOQ genotypes and viral features.
Conclusions: The I148M PNPLA3 variant is associated with adiponectin levels in patients with NAFLD and in healthy
subjects, but in the presence of adiponectin resistance not in CHC patients. The I148M PNPLA3 genotype may
represent a genetic determinant of serum adiponectin levels. Modulation of serum adiponectin might be involved
in mediating the susceptibility to steatosis, NASH, and hepatocellular carcinoma in carriers of the 148 M PNPLA3
variant without CHC, with potential therapeutic implications.
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Paralleling the epidemics of obesity and the metabolic
syndrome (MetS), nonalcoholic fatty liver disease
(NAFLD) has become the leading cause liver disease in
Western countries, affecting 16-34% of the general
population, and a higher proportion of overweight sub-
jects [1]. When complicated by steatohepatitis (NASH),
liver damage can progress to cirrhosis and hepatocellular
carcinoma [2]. NAFLD is defined by an excess of liver
triglycerides in the absence of excessive alcohol intake or
exposure to toxics, and is metabolically characterized by
insulin resistance (IR), which is more severe in the pres-
ence of NASH [3-6]. Increased lipolysis due to adipose
tissue IR is key to NAFLD pathogenesis [5,7], and is
associated with altered release of adipokines, and in par-
ticular adiponectin, a molecule with insulin-sensitizing,
anti-inflammatory, and anti-fibrotic effects [8], whose
decreased levels have been shown to correlate with hep-
atic fat accumulation [9-11]. Adipose tissue IR is
increased, and adiponectin levels decreased, in patients
with severe NASH compared to healthy controls inde-
pendently of body mass, and correlate with histological
improvement after treatment [12]. Overall evidence sug-
gests also the existence of a correlation between adipo-
nectin levels and progressive hepatocellular damage [13].
Defective adiponectin activity has also been demon-
strated in chronic hepatitis C (CHC), but in this case the
mechanism seems related to adiponectin resistance,
leading to hyper-adiponectinemia, especially in patients
with severe fibrosis [14]. However, decreased adiponec-
tin has been associated with steatosis also in CHC [15].
The I148M polymorphism of Patatin-like phospholip-
ase domain-containing 3 (PNPLA3), influences hepatic
triglycerides accumulation and the susceptibility to fi-
brotic NASH in adults and children [16-19], steatosis
susceptibility and liver damage progression in CHC [19-
22], and progression to hepatocellular carcinoma [21].
Although the I148M variant directly interferes with hep-
atic lipid metabolism [23-25], it has also been reported
to influence adipocytes size and leptin transcription in
obese children with NAFLD [26], and in mice deletion
of Pnpla3 influenced gene expression in adipose tissue
[25], thus suggesting that modulation of adipose tissue
function might be involved in the pathogenesis of liver
disease associated with the I148M polymorphism. How-
ever, no data are available on the effect of I148M
PNPLA3 variant on adiponectin levels.
The aim of this study was therefore to assess whether
the I148M PNPLA3 variant influences adiponectin in
patients with liver diseases characterized by altered
adiponectin activity and whose disease progression is
influenced by this genetic variant and steatosis, i.e.
NASH and CHC, and in healthy controls with a verylow probability of steatosis. To increase the power of the
study, the analysis was controlled for adiponectin
(AdipoQ) genotype, which is the major inherited deter-
minant of adiponectin levels [27,28] and was reported
to predispose to steatosis in non-obese non-diabetic sub-
jects [29].
Methods
Patients
We considered 144 consecutive unrelated patients of
Italian ancestry followed at the Metabolic Liver Diseases
outpatient service, Fondazione IRCCS Ca’ Granda Ospe-
dale Maggiore Policlinico, with a new diagnosis of
NAFLD (without cirrhosis) between January 2008 and
January 2010, whose serum (stored at −80°C) and DNA
samples were available. One hundred fifteen patients
underwent liver biopsy because of persistently abnormal
liver enzymes/serum ferritin or a long lasting history
of steatosis associated with severe metabolic abnormal-
ities. Other causes of liver disease were excluded, includ-
ing increased alcohol intake (>30/20 g/day for M/F),
and carboxydesialylated transferrin determination, viral and
autoimmune hepatitis, hereditary hemochromatosis, and
alpha1-antitrypsin deficiency.
We considered 261 Italian patients with CHC, all
with biopsy, followed at the Metabolic Liver Diseases
outpatient service, who were included in a previous
study [21], and for whom a serum sample collected
at the time of liver biopsy and stored at −80°C was
still available.
The control group included 257 blood donors from
Northern Italy who were selected because of availability
of serum samples stored at −80°C, lack of clinical and
biochemical evidence of liver and metabolic disease,
and no alcohol abuse (<30/20 g/day in males/females).
We excluded subjects with ALT> 35/30 IU/ml in males/
females, GGT> 35 IU/ml, BMI > 28, abdominal circum-
ference > 100 cm, glucose levels ≥ 100 mg/dl, triglycer-
ides ≥ 150 mg/dl, HDL ≤ 45/55 in M/F or a fatty liver
index > 35, a value with high specificity to rule out
NAFLD in the general population [30]. The study proto-
col was approved by the Institutional Review Board of
the Fondazione IRCCS Ca’ Granda IRCCS. Informed
written consent was obtained from each patient and
control subject, and the study conforms to the ethical
guidelines of the 1975 declaration of Helsinki. Demo-
graphic and clinical features are shown in Table 1.
Histological assessment
Tissue sections were stained with hematoxylin and
eosin, impregnated with silver for reticulin framework,
and stained with trichrome for collagen. One expert
pathologist unaware of clinical and genetic data reviewed
Table 1 Demographic, clinical, histological, metabolic features, and PNPLA3 I148M genotype of NAFLD and CHC
patients, and healthy controls with very low probability of steatosis
NAFLD patients (n = 144) CHC patients (n = 261) Healthy controls (n = 257)
Sex (F) 32 (22%) 110^ (42%) 55 (21%)
Age (years) 49.5±12 58.1±14^ 48±12
BMI (Kg/m2) 26.8±3.3^ 25.4±3.9 25.0±2.8
Ferritin (ng/ml) 470±420^ 248±372^ 52±47
Total cholesterol (mg/dl) 206±40 178±38^ 193±33
HDL cholesterol (mg/dl) 47±13^ 50±17^ 57±13
Triglycerides (mg/dl) 133±64^ 105±50^ 88±46
Glucose (mg/dl) 98±27^ 95±23^ 67±39
Diabetes 17 (12%)^ 47 (18%)^ 0
ALT (IU/ml) 60±46^ 70±59^ 22±9
GGT (IU/ml) 87±122^ 61±69^ 21±13
Steatosis 144 (100)^ 179 (69)^ 0
Steatosis 2-3 41* (36)^ 23 (9)^ 0
NASH 52* (45) NA NA
Fibrosis 60* (52) 258 (99) NA
Cirrhosis 0 80 (31)^ 0
FFAs (mmol/l)° 0.22 ± 0.01^ NA 0.16±0.01
Insulin (IU/ml)° 14.3 {10.8-20}^ NA 11.7 {9.2-14.5}^
HOMA-IR° 3.2 {2.5-4.8}^ NA 2.5 {1.9-3.2}
Adipo-IR° 14.9±14.5^ NA 6.1±2.7
Adiponectin (μg/ml) 4.9 {3.0-7.8}^ 9.4 {5.7-13.3}^ 6.6 {4.7-9.3}
ADIPOQ
rs2241766TT and rs1501299T+ 83 (57) 143 (55) 142 (55)
rs2241766G+ or rs1501299GG 61 (43) 118 (45) 115 (45)
PNPLA3 rs738409
CC (148 I/I) 55 (38) 133 (51) 146 (57)
CG (148 I/M) 68 (47) 103 (39) 95 (37)
GG (148 M/M) 21 (15) 25 (10) 16 (6)
BMI body mass index, HOMA-IR homeostasis model assessment insulin resistance index, NASH nonalcoholic steatohepatitis, FFAs free fatty acids, Adipo-IR adipose
tissue insulin resistance index, NA not addressed, ():% values, *n = 115 patients with liver biopsy, adiponectin (ADIPOQ) genotype was classified according to [29],
available in all patients and 68 healthy controls, ^p < 0.05 vs. controls.
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features of NASH and fibrosis was assessed according to
Kleiner et al. [31]. NASH was considered to be present
when steatosis, ballooning and lobular inflammation were
present. In CHC patients, liver histology was assessed
according to Ishak [32]. Liver steatosis was also scored
according to Kleiner [31]. The minimum biopsy size was
1.7 cm and the number of portal areas 10.
Adiponectin measurement
All the evaluations have been performed on an aliquot
of plasma collected after overnight fasting collected at
the time of liver biopsy (when available) of the abdom-
inal ultrasonography and metabolic evaluation, which
allowed the diagnosis of NAFLD, and stored at −80°C.Plasma adiponectin levels (all isoforms) were measured
using a commercial enzyme-linked immunosorbent
assay kit with a lowest limit of sensitivity of 0.246 ng/mL
(R&D Sytems, Minneapolis, MN) [33]. Insulin levels
were evaluated in all patients and 68 healthy controls by
the DRG Insulin ELISA kit (DRG International, Moun-
tainside, NJ). Serum FFAs were also evaluated in all
patients and 68 healthy controls by the Free fatty acid
quantification kit (Biovision Research products, Moun-
tain View, CA). Briefly, FFAs are converted to their CoA
derivatives, which are subsequently oxidized with the
concomitant generation of color or fluorescence. C-8
(octanoate) and longer fatty acids generated can then
be easily quantified by colorimetric (spectrophotometry
at λ= 570 nm) methods. The adipose tissue insulin
Table 2 Independent demographic, anthropometric, and
metabolic predictors of the presence of NAFLD at logistic
regression analysis in 212 subjects from Northern Italy
with complete metabolic data
OR 95% c.i. p
Age (years) 1.016 0.98-1.05 0.342
Sex (M) 2.211 0.84-5.81 0.108
BMI (Kg/m2) 1.368 1.17-1.60 <0.0001
Glucose (mg/dl) 0.999 0.97-1.03 0.959
Insulin (IU/ml) 1.173 1.00-1.38 0.055
FFAs (mmol/l) 1.013 1.01-1.02 <0.0001
Adiponectin (μg/ml) 0.870 0.79-0.95 0.003
OR odds ratio, c.i. confidence interval, BMI body mass index, FFAs free
fatty acids.
Valenti et al. BMC Gastroenterology 2012, 12:111 Page 4 of 11
http://www.biomedcentral.com/1471-230X/12/111resistance (Adipo-IR) index was calculated by multiply-
ing fasting FFAs x insulin (mmol/l / pmol/l) [34].
Adiponectin mRNA evaluation
In 35 consecutive patients who underwent gastric band-
ing because of morbid obesity (age 45±10 years, 5 males,
BMI 41.9±7 Kg/m2, 16 with NASH), protocol wedge bi-
opsies of omental visceral adipose tissue (VAT) were
performed as a part of a research protocol for which
approval of the Ethical Committee and written informed
consent were obtained. All patients underwent also liver
biopsy at the time of surgical procedure, and all had liver
steatosis. Total RNA was isolated by the Trizol reagent
(Lifetech, Carlsbad, CA), digested with DNaseI, and
quality evaluated by measuring the 260/280 nm absorb-
ance ratio (≥ 1.8) and by electrophoresis. First-strand
cDNA was synthesized using equal amounts (0.5 μg) of
total RNA, with the SuperScript VILO cDNA synthesis
kit (Invitrogen, Carlsbad, CA). Adiponectin mRNA levels
were analyzed by qRT-PCR with SYBR Green chemistry
(Fast SYBR Green master mix, Applied Biosystems,
Foster City, CA). All the reactions were performed in
triplicate with the ABI 7500fast quantitative real time
(qRT)-PCR system (Lifetech, Carlsbad, CA). Primers
are available upon request. Results were normalized for
beta actin and HPRT1, which were chosen as a control
because of stable expression among different samples,
and reported as arbitrary units (i.e. fold expression rela-
tive to normalized adiponectin expression of a control
sample used as internal standard for calibration of qRT-
PCR reactions).
Genetic analysis
DNA was extracted from peripheral blood by the
phenol-chloroform method. The adiponutrin/PNPLA3
rs738409 C>G SNP, encoding I148M, was genotyped by
a Taqman assay (assay on demand for rs738409, Applied
Biosystems, Foster City, CA) by personnel unaware
of patients and controls clinical status. Post-PCR allelic
discrimination was carried out measuring allele-specific
fluorescence on the Opticon2 detection system (MJ
Research, Waltham, MA) [17]. Adiponectin (ADIPOQ )
rs2241766, +45 G>T and r150299, +276 G>T poly-
morphisms, previously associated with the susceptibility
to NAFLD [29], were also genotyped by a Taqman assay
(assay on demand, Applied Biosystems, Foster City, CA).
Statistical analysis
Results are expressed as means ± standard deviation for
normally distributed variables, median {interquartile
range} for non-normally distributed variables (e.g. adipo-
nectin), which were log transformed before analysis.
Mean values were compared by Anova or Wilcoxon,
when appropriate, and frequencies by Fisher’s exact test.Variables were correlated by the Spearman’s rho test.
Independent predictors of the presence of NAFLD,
NASH, and fibrosis, and of low adiponectin levels were
determined by logistic regression analysis. Analyses
were carried out with the PASW 18.0 (SPSS - IBM,
Chicago, IL) and the JMP 6.0 (SAS, Cary, NJ) statistical
analysis software.
Results
Adiponectin levels are associated with NAFLD
As expected, despite similar sex distribution, patients
with NAFLD had higher BMI, prevalence of dyslipide-
mia, IR, increased liver enzymes NAFLD, serum insulin
(p < 0.0001), FFAs (p < 0.0001), HOMA-IR (p < 0.0001),
Adipo-IR (p < 0.0001), and lower adiponectin levels
(p = 0.008) compared to healthy controls with very low
probability of steatosis (Table 1). At multivariate logistic
regression analysis conducted in patients and controls
with complete metabolic data, FFAs (OR 1.013, 95% c.i.
1.007-1.018; p < 0.0001) and adiponectin (OR 0.870, 95%
c.i. 0.794-0.953; p = 0.003) were associated with NAFLD
independently of age, sex, BMI, glucose, and insulin
levels (Table 2).
Adiponectin, steatosis, and liver damage in subjects
with NAFLD
Adiponectin levels were correlated with serum FFAs
(rho =−0.141; p = 0.043), Adipo-IR (rho =−0.155; p =
0.026), ALT levels (rho =−0.411; p < 0.0001), severity of
steatosis (rho = 0.200; p = 0.033), necroinflammation
(rho =−0.297; p = 0.001), NAFLD activity score (rho =
−280; p = 0.003), and fibrosis stage (rho =−0.297,
p = 0.001), and was inversely correlated with fasting insu-
lin (rho =−0.156, p = 0.002). Independent predictors of
steatosis grade 2–3, NASH, and the presence of fibrosis
in biopsied patients are shown in Table 3. Adiponectin
levels were associated with a reduced risk of moderate/
severe steatosis (OR 0.83, 95% c.i. 0.72-0.96), NASH (OR
Table 3 Independent predictors of steatosis grade 2–3, NASH, and of fibrosis at logistic regression analysis in 115
consecutive biopsied patients with NAFLD with available DNA and serum samples at the time of liver biopsy
Variables Steatosis grade 2–3 vs. 1 NASH vs. simple steatosis Fibrosis vs. no fibrosis
OR (95% c.i.) p value OR (95% c.i.) p value OR (95% c.i.) p value
Age (years) 1.04 (0.99-1.09) 0.094 1.01 (0.96-1.06) 0.598 1.06 (1.01-1.10) 0.020
Sex (F) 1.31 (0.40-4.2) 0.656 0.88 (0.27-2.89) 0.834 0.55 (0.18-1.65) 0.282
BMI (Kg/m2) 1.22 (1.04-1.44) 0.014 1.32 (1.11-1.56) 0.002 1.13 (0.99-1.30) 0.079
ALT (IU/ml) 1.02 (1.01-1.03) 0.007 1.01 (1.00-1.02) 0.028 1.01 (1.00-1.02) 0.028
Glucose (mg/dl) 0.99 (0.98-1.01) 0.217 1.03 (1.00-1.05) 0.061 1.02 (0.99-1.04) 0.214
Insulin (IU/ml) 1.01 (0.97-1.06) 0.618 0.99 (0.94-1.04) 0.654 0.98 (0.94-1.03) 0.473
FFAs (mmol/l) 1.00 (0.98-1.01) 0.453 1.00 (0.99-1.01) 0.671 1.00 (0.99-1.01) 0.934
Adiponectin (μg/ml) 0.83 (0.72-0.96) 0.012 0.86 (0.75-0.98) 0.025 0.84 (0.74-0.95) 0.006
OR odds ratio, c.i. confidence interval, BMI body mass index, FFAs free fatty acids; the presence of NASH and fibrosis were defined according to the NASH clinical
research network definition [31].
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0.74-0.95) independently of age, sex, BMI, ALT, insulin,
glucose levels, and FFAs.
PNPLA3 genotype influences adiponectin levels in
subjects without viral hepatitis
The frequency distribution of the I148M PNPLA3 vari-
ant was significantly different between patients and con-
trols (p < 0.0001; Table 1), due to an over-representation
of the 148 M variant in patients, whereas ADIPOQ geno-
type was not significantly associated with NAFLD (in
both male and females). Clinical features of patients and
controls with very low probability of steatosis subdivided
according to PNPLA3 I148M are shown in Table 4.
PNPLA3 I148M genotype was associated with adipo-
nectin levels both in patients (p = 0.03) and in con-
trols (p = 0.04), whereas it did not influence other
metabolic features.
In contrast, ADIPOQ genotype was associated with
adiponectin levels in controls (7.6±3.8 in rs2241766TT
and rs1501299T+ vs. 6.8±3.8 μg/ml in rs2241766G+ or
rs1501299GG; p = 0.048), but not in patients with
NAFLD (not shown). The difference was more marked
in males (6.9±3.5 in rs2241766TT and rs1501299T+ vs.
5.8±3.4 μg/ml in rs2241766G+ or rs1501299GG;
p = 0.021), whereas it was not significant in females
(not shown). Adiponectin levels in subjects subdivided
according to PNPLA3 genotype after stratification for
gender and the presence of NAFLD are shown in
Figure 1A. In this subgroup analysis, the I148M variant
was significantly associated with adiponectin in females
with NAFLD.
In the whole series of subjects without CHC (Table 5),
low adiponectin levels (lower than 6 μg/ml, median
value in controls) were associated with the presence of
NAFLD, age, male gender, BMI, dyslipidemia, ALT, insu-
lin levels, PNPLA3 I148M alleles (p = 0.01), and ADIPOQ
genotype (p = 0.009). Interestingly, the 148 M PNPLA3allele was associated with low serum adiponectin in sub-
jects carrying the ADIPOQ rs2241766G+or rs1501299GG
“low adiponectin” genotypes (50, 47% 148I/I; 64, 65% I/M,
20, 80%, M/M; p = 0.0018), but not in those with the
rs2241766TT and rs1501299T+ “high adiponectin” geno-
types (47, 46% 148I/I; 30, 45% I/M, 6, 46%, M/M;
p = 0.99). At logistic regression analysis (Table 5), low
adiponectin levels were associated with NAFLD diag-
nosis, younger age, male sex, higher BMI, ADIPOQ
genotype, and PNPLA3 148 M alleles (OR 1.67, 95% c.i.
1.07-2.64 for each 148 M allele carried). In patients with
histological NAFLD, PNPLA3 148 M alleles were asso-
ciated with low adiponectin levels independently of age,
sex, BMI, ADIPOQ genotype, and the severity (grade 1
to 3) of steatosis (OR 2.20, 95% c.i. 1.09-4.80; p = 0.027).Effect of I148M PNPLA3 on adiponectin expression in VAT
As expected, in severely obese patients VAT adiponectin
mRNA levels tended to be lower in patients with
(n = 16) than in those without (n = 19) NASH (2.9±2.9
vs. 5.5±5.8 arbitrary units (AU); p = 0.1). In this series
adiponectin was not significantly associated with gender
(possibly due to the very small number of males
included), age, and BMI. Adiponectin mRNA levels
according to PNPLA3 genotype and NASH are shown in
Figure 1B. The presence of the 148 M variant was asso-
ciated with lower adiponectin even in the absence of
NASH (2.2±2, n = 10 vs. 9.0±10, n = 9; p = 0.050).Effect of PNPLA3 genotype on adiponectin levels
in CHC patients
Clinical features of CHC patients subdivided according
to PNPLA3 genotype are presented in Table 6. PNPLA3
genotype was associated with steatosis (p = 0.02), severe
steatosis (p < 0.0001), and nearly associated with cirrho-
sis (p = 0.06), but was not significantly associated with
metabolic features.
Table 4 Clinical features of 144 NAFLD patients and 257 healthy controls with very low probability of steatosis from
Northern Italy according to the PNPLA3 I148M genotype
NAFLD patients (n = 144) p value*
PNPLA3 genotype CC (n = 55) CG (n = 68) GG (n = 21)
Age (years) 49±13 51±12 47±12 0.87
Sex (F) 15 (27) 12 (18) 5 (24) 0.58
BMI (Kg/m2) 26.8±3.7 27.1±3.1 26.0±3.0 0.62
ALT (IU/ml) 54±38 58±49 80±54 0.06
Diabetes 3 (5.5) 11 (16.2) 3 (14.3) 0.13
Insulin (IU/ml) 14.6 {11.7-19.9} 13.4 {10.2-20.2} 16.8 {11.5-22.1} 0.33
Glucose 94±21 101±34 97±16 0.43
HOMA-IR 3.1 {2.5-4.5} 3.3 {2.4-4.5} 3.3 {2.4-5.5} 0.57
FFAs (mmol/l) 0.21±0.09 0.22±0.08 0.22±0.09 0.85
Adipo-IR 14.2±15.1 13.9±13.9 17.9±15.4 0.78
Adiponectin (μg/ml) 5.5 {3.0-9.9} 4.9 {3.0-7.4} 3.8 {2.7-6.5} 0.03
Controls (n = 257) p value*
PNPLA3 genotype CC (n = 146) CG (n = 95) GG (n = 16)
Age (years) 46±12 51±12 45±14 0.51
Sex (F) 37 (25) 15 (16) 3 (19) 0.83
BMI (Kg/m2) 24.8±2.7 25.2±2.8 25.2±4.2 0.71
ALT (IU/ml) 21±7 24±8 22±6 0.48
Insulin° (IU/ml) 11.8 {9.5-14.0} 11.9 {9.2-15.4} 9.0 {7.6-14.8} 0.17
Glucose 89±6 89±6 86±3 0.89
HOMA-IR° 2.5 {1.9-3.2} 2.6 {2.0-3.4} 1.8 {1.7-3.0} 0.10
FFAs° (mmol/l) 0.16±0.07 0.14±0.06 0.23±0.02 0.93
Adipo-IR° 6.4±2.8 5.2±2.1 8.1±0.9 0.47
Adiponectin (μg/ml) 7.0 {4.7-9.9} 6.2 {4.7-8.8} 5.6 {4.2-7.4} 0.04
* p for trend across PNPLA3 genotypes, °available in 68 controls. BMI body mass index, IFG impaired fasting glucose, HOMA-IR homeostasis model assessment
insulin resistance index, FFAs free fatty acids, Adipo-IR adipose tissue insulin resistance index, ():% values, {}: interquartile range.
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(with and without steatosis) than in those without CHC
(NAFLD patients and healthy controls): 9.4 {5.7-13.2} vs.
5.8 {3.9-8.9} μg/ml; p < 0.0001. At multivariate logistic
regression analysis, the association between adiponectin
and CHC was independent of age, gender, BMI, the
presence of steatosis, and ADIPOQ genotype (OR 1.10,
95% c.i. 1.03-1.19; p = 0.0009). Variables associated with
low adiponectin levels in CHC patients are shown in
Table 7. Low adiponectin levels were associated with
steatosis, age, male gender, dyslipidemia, cirrhosis, and
viral genotype 4 (patients carrying genotype 4 were
all males), nearly associated with ADIPOQ genotype
(p = 0.068), but not with PNPLA3 I148M genotype
(p = ns). However, there was an association between
the 148 M/M genotype low adiponectin levels in sub-
jects carrying the “high adiponectin” rs2241766TT and
rs1501299T+ genotypes (6, 46% vs. 20, 19%; p = 0.026).
There was no significant association between adipo-
nectin and viral load, other viral genotypes, and thehistological activity of the disease (not shown). At logis-
tic regression analysis (Table 7), low adiponectin levels
were associated with male sex, younger age, and steato-
sis, but not with PNPLA3 and ADIPOQ genotypes.
Discussion
As decreased adiponectin, a molecule which antagonizes
hepatic lipid accumulation and has insulin-sensitizing,
anti-inflammatory, and anti-fibrotic effects [8] plays
a pivotal role in NAFLD pathogenesis [9-11,13], and
the I148M PNPLA3 polymorphism involved in the regu-
lation of lipid metabolism predisposes to the prog-
ression of liver diseases associated with steatosis by
still undefined mechanisms, we evaluated whether
PNPLA3 genotype influenced adiponectin levels. Our
results support the hypothesis that PNPLA3 genotype is
a determinant of serum adiponectin in patients with
NAFLD, in particular in females, and in healthy con-
trols, independently of acquired factors, and of ADIPOQ
[27,28].
Figure 1 Effect of PNPLA3 genotype on serum adiponectin. A) Adiponectin levels according to I148M PNPLA3 genotype in subjects stratified
according to gender and NAFLD diagnosis vs. healthy controls. B) Adiponectin mRNA levels (AU: arbitrary units) in VAT of morbidly obese
patients according to the presence of NASH and I148M PNPLA3 genotype.
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http://www.biomedcentral.com/1471-230X/12/111We preliminarily confirmed that patients with NAFLD
displayed lower adiponectin than healthy controls [13].
Although we did not exclude steatosis by imaging in all
control subjects, the metabolic and clinical selection cri-
teria used have a high specificity to exclude this condi-
tion in the general population [30], and the different
distribution of PNPLA3 genotype between patients and
healthy subjects with very low probability of steatosis in-
directly confirmed the accurate selection of controls
[16,17]. Moreover, in patients with NAFLD low adipo-
nectin was independently associated with the severity of
steatosis, as well as with NASH and fibrosis, in line withthe hypothesized role of adiponectin in the progression
of liver damage [9,11,13,35].
The I148M PNPLA3 variant is a major risk factor
for the development and progression of NAFLD
[16-18, 22,36], but the mechanism linking the 148 M
allele to increased liver fat, inflammation, and fibro-
genesis, and the tissue specificity of PNPLA3 physio-
logical activity are still under definition [25,37]. The
148 M PNPLA3 allele was previously associated with
adipocytes of smaller size, a marker of metabolic derange-
ment, and increased leptin transcription in a small group
of obese children with NAFLD [26], thus suggesting that
Table 5 Variables associated with and independent predictors of low adiponectin levels (<6 mg/ml) in 144 NAFLD
patients and 257 healthy controls with very low probability of steatosis
Adiponectin Low (n = 217) High (n= 194) p OR * (95% c.i.) p *
NAFLD present 89 (46) 52 (24) 0.002 1.65 (1.02-2.70) 0.043
Age (years) 46±11 51±13 0.007 0.96 (0.94-0.98) <0.0001
Sex (F) 20 (9) 67 (34) <0.0001 0.21 (0.11-0.37) <0.0001
BMI (Kg/m2) 26.2±3.0 25.0±3.1 <0.0001 1.15 (1.07-1.25) 0.0002
HDL (mg/dl) 48±12 57±14 <0.0001 - -
Triglycerides (mg/dl) 119±68 92±47 <0.0001 - -
ALT (IU/ml) 42±38 29±25 <0.0001 - -
Insulin (IU/ml) 17±14 13±8 0.003 - -
FFAs (mmol/l) 0.21±0.09 0.19±0.08 0.05 - -
ADIPOQ
rs2241766TT and rs1501299T+ 83 (38) 100 (52) 0.008 0.61 (0.39-0.95) 0.030
rs2241766G+ or rs1501299GG 134 (62) 94 (48) reference
PNPLA3 rs738409
CC (148 I/I) 97 (45) 112 (58) 0.01 1.67° (1.07-2.64) 0.024
CG (148 I/M) 94 (43) 71 (37)
GG (148 M/M) 26 (12) 11 (6)
():% values; * OR of low adiponectin at logistic regression analysis considering as independent variables the presence or not of NAFLD, age, gender, BMI, ADIPOQ
and PNPLA3 genotype (additive model; OR per number of variant 148 M alleles).
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http://www.biomedcentral.com/1471-230X/12/111modulation of adipose tissue endocrine activity may be
implicated in the mechanism by which PNPLA3 influ-
ences NASH susceptibility. In the present study, we could
not detect a significant association between PNPLA3,
FFAs, and insulin resistance [36], whereas in line with the
experimental hypothesis PNPLA3 genotype influenced
serum adiponectin levels. Indeed, we observed a dose
dependent relationship between the 148 M variant andTable 6 Clinical features of 261 CHC patients from Northern I
PNPLA3 genotype CC n=133 (51) C
Age (years) 57±14
Sex (F) 58 (44)
BMI (Kg/m2) 25.2±3.4
ALT (IU/ml) 72±56
Diabetes 26 (20)
Insulin (IU/ml) 21 {14–27}
Glucose 95±22
Total cholesterol (mg/dl) 176±36
HDL cholesterol (mg/dl) 50±15
Triglycerides (mg/dl) 108±43
HOMA-IR 4.7 {3.2-5.8}
Adiponectin (μg/ml) 9.3 {5.8-13}
Steatosis 85 (64)
Severe steatosis (> 33%) 8 (6)
Cirrhosis 34 (26)
():% values; {}: interquartile range, reported with median value; *p < 0.05 vs. other gadiponectin, which was evident in both in healthy con-
trols and patients with NAFLD, but, due to the very well
known gender-specific dimorphism of adiponectin levels
which are higher in females [8], it more frequently con-
tributed to hypo-adiponectinemia in females. Interest-
ingly, these data may contribute to explain the significant
interaction between PNPLA3 I148M genotype and female
gender on NAFLD risk observed in the recent meta-taly according to the PNPLA3 I148M genotype
G n=103 (39) GG n=25 (10) p value
59±14 57±14 0.47
46 (45) 6 (24) 0.16
25.3±3.9 26.6±6.1 0.25
67±58 73±78 0.81
17 (17) 4 (16) 0.80
20 {17–27} 17 {12–25} 0.61
96±26 93±22 0.85
177±41 178±41 0.95
51±18 48±15 0.66
104±61 88±31* 0.24
4.5 {3.4-6.6} 3.8 {2.3-6.5} 0.62
9.4 {5.7-14} 9.7 {5.3-13} 0.93
72 (70) 22 (88) 0.02
7 (7) 8 (32) <0.0001
36 (35) 10 (40) 0.06
enotypes.
Table 7 Variables associated with and independent predictors of low adiponectin serum levels (<6 μg/ml) in 261 CHC
patients
Adiponectin Low (n = 72) High (n = 189) p OR * (95% c.i.) p *
Steatosis present 59 (82) 120 (63) 0.004 3.85 (1.78-8.91) 0.0005
Age (years) 51±14 61±13 <0.0001 0.95 (0.92-0.97) <0.0001
Sex (F) 10 (14) 100 (53) <0.0001 0.18 (0.08-0.38) <0.0001
HDL (mg/dl) 42±11 53±17 <0.0001 - -
Triglycerides (mg/dl) 121±71 98±38 0.012 - -
Cirrhosis 15 (21) 65 (34) 0.036 0.65 (0.30-1.40) 0.277
Viral genotype 4 11 (15) 8 (4) 0.0055 1.68 (0.55-5.70) 0.456
ADIPOQ
rs2241766TT and rs1501299T+ 26 (36) 92 (49) 0.068 0.74 (0.39-1.40) 0.355
rs2241766G + or rs1501299GG 46 (64) 97 (51) reference
PNPLA3 rs738409
CC (148 I/I) 34 (47) 99 (52) 0.73 1.15 (0.71-2.80) 0.600
CG (148 I/M) 30 (42) 73 (39)
GG (148 M/M) 8 (11) 17 (9)
():% values; * OR of low adiponectin values at logistic regression analysis considering as independent variables the presence or not of NAFLD, age, gender, BMI,
ALT, and ADIPOQ and PNPLA3 genotype (additive model; OR per number of 148 M alleles).
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http://www.biomedcentral.com/1471-230X/12/111analysis by Sookoian et al. [36]. The observation that even
in the absence of NASH severely obese patients carrying
the 148 M variant had decreased VAT adiponectin mRNA
expression is also in line with these findings and suggests
that the reduced serum adiponectin associated with this
genetic polymorphism is determined by impaired tran-
scription of the gene in the adipose tissue. However, given
the relatively limited number of subjects analyzed (in par-
ticular of obese subjects), the relationship between
PNPLA3 genotype and adiponectin, and the lack of
association with IR should be confirmed in further stud-
ies. Indeed, recent studies have reported an association of
the PNPLA3 I148M variant with IR and lower levels of
triglycerides in severely obese subjects [38,39], suggesting
that in the presence of environmental triggering factors
PNPLA3 is indeed a modulator of hepatic IR and lipopro-
tein secretion.
Furthermore, although the association between PNPLA3
genotype and adiponectin was independent of steatosis se-
verity in patients with NAFLD, our results does not ex-
clude that PNPLA3 may modulate adipose tissue
indirectly by regulating the secretion of hepatokines such
as fetuin [40], and that it may also modulate other pro-
inflammatory molecules such as resistin and ICAM-1
[26,41].
The genetic determinants of serum adiponectin levels,
a strongly heritable trait, have been recently evaluated
in genome-wide association studies [27,28]. Although
no association with PNPLA3 has emerged so far, only
a small fraction (<10%) of adiponectin heritability
has been determined, and none of the studies con-
sidered patients with NAFLD. The strongest geneticdeterminant of adiponectin levels is ADIPOQ [27,28],
and ADIPOQ SNPs have been associated with steatosis
and progressive NASH in lean patients without diabetes
and dyslipidemia [29]. In this study, we characterized
ADIPOQ genotype, which allowed to adjust the results
for a major confounder and to unveil a possible inter-
action between ADIPOQ and PNPLA3 in determin-
ing adiponectin levels. The lack of association between
ADIPOQ and NAFLD risk may be explained by the dif-
ferent inclusion criteria in our study compared to the
previous [29].
On the other hand, despite in line with previous find-
ings PNPLA3 genotype influenced steatosis in CHC and
was possibly associated with lower triglycerides, in these
patients PNPLA3 and ADIPOQ were not significantly
associated with adiponectin, possibly due to develop-
ment of adiponectin resistance associated with chronic
HCV infection, in particular in patients with more
severe disease [14]. Adiponectin resistance could modify
the interaction between genotype and environmental
factors, decreasing the effect size of genetic variants, so
that the power of the present study was not sufficient
to detect significant differences in adiponectin levels.
This conclusion is supported by our data indicating that
CHC is independently associated with higher adipo-
nectin, previously ascribed to decreased adiponectin
receptor-1 mediated clearance [14], in particular in the
presence of advanced fibrosis [14]. In contrast, although
cirrhotic patients were not included in the NAFLD
group, adiponectin levels decreased with the severity of
liver damage in patients with steatosis, in line with the
results of a recent meta-analysis [13].
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In conclusion, our data suggest that the I148M PNPLA3
genotype may represent a genetic determinant of serum
adiponectin levels. Modulation of serum adiponectin
might be involved in mediating the susceptibility to stea-
tosis, NASH, and hepatocellular carcinoma in carriers of
the 148 M PNPLA3 variant without CHC, with potential
therapeutic implications, but additional studies are
required to confirm this hypothesis.
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